Top 5 Biotech Angel Investors in Belgium (October 2023)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Annie Vereecken
Angel
|
4 | Belgium | Seed, Series A | Biotechnology, Medical, Hospital | |
|
Pierre Drion
Angel
|
3 | Belgium | Series A, Series B | Biotechnology, Life Science, Software | |
|
Luc Vauterin
Angel
|
2 | Belgium | Seed, Series A | Life Science, Data Integration, Data Visualization | |
|
Herman Verrelst
Angel
|
1 | Belgium | Series A | Medical, Hospital, Biotechnology | |
|
Kenneth Buckfire
Angel
|
1 | Belgium | Series A | Medical, Health Care, Life Science | |
| Access all 5 angel investors in Belgium Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Investor list
Annie Vereecken
Show more...Investment focus
- Industry: Biotechnology, Medical, Hospital
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Pierre Drion - CEO @ Petercam
Show more...Investment focus
- Industry: Biotechnology, Life Science, Software
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 5
- Lead/follow: no public data
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.
Luc Vauterin - Board Member @ ONTOFORCE
Show more...Investment focus
- Industry: Life Science, Data Integration, Data Visualization
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Herman Verrelst
Show more...Investment focus
- Industry: Medical, Hospital, Biotechnology
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- UgenTec — FastFinder is intelligent software that automates sample workflow, ensures your assays are analyzed consistently and cuts data analysis time in half.
Kenneth A. Buckfire is Co-President and co-founder of Miller Buckfire. Over the course of his career he has advised clients in a broad range of industries (including energy, food products, building products, broadcasting and information services) and has also managed principal investments in distressed companies and in the utility industry. Mr.Buckfire advised Calpine Corporation (named “Most Outstanding Mega Turnaround of 2008″ by the Turnaround Management Association) in its January 2008 reorganization. In 1998, Mr. Buckfire advised 19 independent power producers in the 1998 restructuring of their $11 billion in power contracts with Niagara Mohawk Power Corporation (named “Energy Deal of 1998” by Investment Dealers Digest). Mr. Buckfire has played a leading role in the restructurings of Standard Pacific Corp., Calpine Corporation, Level (3) Communications, Exide Technologies, McLeodUSA, ICG Communications, PSINet Inc., Sirius Satellite Radio, BTI Telecom, CMS Energy, CenterPoint Energy, General Growth Properties, Mirant Corporation (Creditors’ Committee), Horizon Natural Resources (named “Most Outstanding Transaction of 2005” by the Turnaround Management Association), Oakwood Homes, TECO Energy, Centennial Communications, Allegheny International, Foamex, Van Camp Seafood, Walter Industries, Burnham Broadcasting, EUA Power Corporation, Dialog Corporation, Imperial Sugar, CRIIMI MAE and Cajun Electric.Prior to founding Miller Buckfire, Mr. Buckfire was a Managing Director at Dresdner Kleinwort Wasserstein and served as Co-Head of the firm’s financial restructuring group specializing in the restructuring and refinancing of highly leveraged companies. Before joining DrKW, Mr. Buckfire was a Senior Vice President at Lehman Brothers Inc. Mr. Buckfire is on the board of advisors of the Zell-Lurie Institute at The University of Michigan, and on the Board of Directors of the Philharmonic Symphony Society of New York. He is a trustee of Orpheus Orchestra, a member of the Weil Cornell Medical College Dean’s Council, and has been a director and co-founder of several public and private corporations. Mr. Buckfire received his M.B.A. from Columbia University (1987) and his B.A. in Economics and Philosophy from The University of Michigan (1980).
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Angel Investors in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 angel investors investing in Belgium Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Sign up with Google
Sign up with LinkedIn
